UK plans revised gene therapy classification

UK plans revised gene therapy classification

Britain plans updated definitions for emerging gene therapy products nationwide. The MHRA-backed changes would extend established advanced therapy classification to certain synthetic nucleic acid treatments and genome-editing technologies, subject to parliamentary approval.


The UK government has backed changes to the legal definition of gene therapy medicinal products, allowing certain synthetic genetic medicines and newer genome-editing treatments to be classified under the country’s established advanced therapy framework.

The decision, confirmed on 19 November, follows a consultation led by the Medicines and Healthcare products Regulatory Agency (MHRA) and Northern Ireland’s Department of Health. The proposals received support from 83% of respondents and will now progress towards legislation.

Amendments to the Human Medicines Regulations 2012 remain subject to international notification procedures and parliamentary approval. Existing requirements for medicine quality, safety and efficacy will be maintained, while products that have already been licensed will not need to be reclassified.

Current UK legislation identifies gene therapy medicinal products as a category of advanced therapy medicinal product. The underlying definition originated in 2007, when the manufacturing technologies and biological mechanisms available to medicine developers were substantially different from those used in more recent research programmes.

Gene therapy development now includes chemically synthesised genetic material, genome editing technologies and cell-based approaches that do not necessarily rely on the recombinant nucleic acid systems anticipated by the original wording.

Some of these medicines can therefore present classification difficulties even when their intended therapeutic function resembles that of a treatment already regulated as a gene therapy. The starting material or mechanism used to produce a genetic effect may prevent a product from meeting the existing legal definition.

Under the proposed changes, classification would be determined more directly by the characteristics of the active substance and the mechanism through which it operates. The revised approach would encompass certain medicines containing recombinant or synthetic nucleic acids that undergo transcription or translation, as well as products involving sequence-specific genome editing.

Transcription is the process through which genetic information is used to produce RNA, while translation uses information carried by RNA to produce a protein. These processes can form part of the therapeutic mechanism used by medicines that introduce or regulate genetic information.

A synthetic nucleic acid may be designed to perform a function comparable with material produced through a biological manufacturing route. Under the existing definition, however, its non-biological origin can create a different regulatory classification despite the similarity in the resulting mechanism.

The MHRA’s consultation identified this distinction as a weakness in the present framework. Updating the definition would allow qualifying synthetic products to be assessed through the advanced therapy route rather than leaving their classification dependent on whether the starting material was biologically derived.

Genome editing presents a related problem. Newer technologies can make targeted changes to genetic sequences without using the recombinant nucleic acid systems contemplated by the original legislation. Some approaches can also involve editing cells before they are administered to a patient.

The proposed definition would cover medicines involving sequence-specific modification of a target genome, including relevant products containing cells that have undergone such changes. Classification would no longer depend solely on whether the editing mechanism used a conventional recombinant construct.

These changes could affect the planning of manufacturing and development programmes. A product’s legal classification determines which regulatory framework applies to its development, quality assessment, clinical evidence and subsequent licensing application.

Advanced therapies can involve complex manufacturing processes, including the handling of biological materials, production of genetic components, cell processing and the control of specialised delivery systems. Their quality requirements must reflect the characteristics and potential risks of the finished medicine.

Materials used during development may also differ from those employed when production is expanded. Changes in starting materials, manufacturing equipment or processing conditions require appropriate evaluation to establish whether the resulting product remains consistent with the material used to support its development.

For manufacturers, clearer classification can reduce uncertainty when deciding how to design analytical methods, establish production controls and prepare regulatory documentation. It does not eliminate the work required to demonstrate that a particular manufacturing process can consistently produce material meeting the necessary specifications.

The MHRA has confirmed that existing approval standards will remain in place. Products brought within the revised definition will still be subject to the applicable requirements governing quality, safety and efficacy, including manufacturing and clinical standards relevant to the particular medicine.

The consultation also makes clear that advanced therapy classification should not be treated as a simple indication of a product’s risk. The characteristics of an individual medicine, its intended use, delivery mechanism and potential effects determine the evidence needed to support its assessment.

Conducted between 11 May and 22 June 2026, the consultation received responses from pharmaceutical and biotechnology companies, academic organisations, NHS bodies, professional associations and patient representatives.

Support for the proposed approach reached 83% of respondents. This represents the consultation result rather than a finding that the entire UK pharmaceutical sector has endorsed the changes.

The government’s decision was confirmed during London Life Sciences Week, following the DIA-MHRA Global Summit held on 16 and 17 November. The MHRA will now progress the legislative work needed to amend the current definition.

Until the amendments are approved and brought into force, developers must continue to work within the existing legal framework. The new approach is intended to provide clearer classification for emerging therapies without changing the evidence required before a medicine can be authorised for use.


Stories for you


  • EU industry committee fails to agree ETS opinion

    EU industry committee fails to agree ETS opinion

    EU lawmakers failed to agree an industrial emissions trading opinion. Manufacturers have renewed calls for changes to free allowance allocation, industrial benchmarks and carbon border measures ahead of the post-2030 ETS review.


  • EU negotiators agree two-year methane reporting delay

    EU negotiators agree two-year methane reporting delay

    European lawmakers have agreed delayed deadlines for methane reporting obligations. The provisional agreement would give fossil fuel importers until January 2029 for specified monitoring requirements, while methane intensity reporting for importers and EU producers would move to August 2030.